SRX Global agrees to acquire CERo Therapeutics unit in stock and debt deal
On October 6, 2026, SRX Global entered a Stock Purchase Agreement to acquire all outstanding stock of CERo Therapeutics, Inc., a wholly owned subsidiary of CERo Therapeutics Holdings, Inc. Consideration includes $1,000,000 in SRX common stock, discharge of a senior secured note with an outstanding principal balance of $8,249,643.77, and assumption of about $1,562,000 in liabilities. Completion depends on a 30-day go-shop period, the acquisition of Holdings' Series C, D and E preferred stock, and conditions tied to its Series A preferred stock, so shareholders face both the share issuance and the uncertainty of closing.
Key points
- Consideration: $1,000,000 of SRX common stock, discharge of the Consolidated Note (outstanding principal $8,249,643.77 as of the filing date), and assumption of about $1,562,000 in liabilities
- 30-day go-shop period from the October 6, 2026 signing, conducted by Joseph Gunnar & Co., LLC, during which Holdings may solicit alternative proposals
- Holdings must pay a $750,000 termination fee in specified cases; SRX may owe Holdings $750,000 in specified cases involving its failure to fund
- Closing requires SRX to acquire Holdings' Series C, D and E preferred stock; the agreement is not subject to a financing condition
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.